02/17/2021

Medicare Payment for Physician-Administered (Part B) Drugs: The Interim Final Rule and a Better Way Forward

On November 27, 2020, the Trump administration published in the Federal Register an interim-final rule to use Medicare’s demonstration authority under the Center for Medicare and Medicaid Innovation (CMMI) to make large reductions in the amounts it pays physicians for high-cost medicines they administer under Part B. The goal is to lower payments to be more in line with prices in other advanced countries.  This rule addresses a real problem—that prices for many Part B drugs are effectively constrained by neither market forces nor regulations—but deals with it in a flawed manner.  READ MORE